Description
+ Include: 27 videos, size: 3.45 GB
+ Target Audience: oncologists
+ Sample video: contact me for sample video
+ Information:
The International Ultmann Chicago Lymphoma Symposium (IUCLS) is an annual conference dedicated solely to the science and clinical care of lymphoma. It has been organized to honor the achievements of Dr. John Ultmann, a pioneer in the treatment of lymphoma, who devoted his life to the understanding of this disease. He was particularly known for his work on the staging of Hodgkin lymphoma and the utility of staging as a guide for treatment.
We are fortunate to have a multitude of the world’s experts in lymphoma speak each year at the conference. The audience is comprised of regional practicing oncologists, advanced nurse practitioners and physician assistants, residents, fellows, and the Chicago academic community that includes five academic centers.
This is a certified continuing medical education (CME) activity that focuses on the biologic, diagnostic, and therapeutic aspects of Hodgkin lymphoma and non-Hodgkin lymphoma. This year’s meeting will be a 2-day live meeting to discuss recent updates in the care of patients with solid and hematologic malignancies. A virtual live stream option will also be available for participants unable to travel.
Target Audience
Learning Objectives
At the conclusion of this educational activity, participants will be able to:
-
Compare and contrast the latest approaches to the treatment of patients with indolent and aggressive forms of non-Hodgkin lymphoma;
-
Evaluate current and emerging approaches to the treatment of patients with Hodgkin lymphoma;
-
Assess the latest clinical trial data of current and emerging CAR T-cells and cellular therapy for patients with hematologic malignancies, including important safety and efficacy data;
-
Discuss patient and disease-related factors that impact the selection and sequencing of therapy for patients with CLL;
-
Develop strategies to utilize the entire multidisciplinary team during the continuum of care of patients with lymphoma.
+ Topics:
Biology of Follicular Lymphoma.ts
Bispecific Antibodies in Lymphomas.ts
CAR T-Cell Constructs in Lymphoma Current and Future Options.ts
CAR T-Cell Therapy and Emerging Bispecifics for the Treatment of Follicular Lymphoma.ts
Cellular Therapy in Lymphoma Where Are We Now.ts
CLL Present and Future.ts
COVID-19 in Patients With Lymphoma Treatment Approaches, Vaccination, and Prophylactic Strategies.ts
Debate Auto-HCT Remains the Preferred Standard of Care for 1L Therapy of MCL.ts
Debate We Should Stop Doing Autotransplants for Patients With MCL in 1st Remission.ts
Follicular Lymphoma Management in the COVID-19 Era.ts
High-Grade B-Cell Lymphomas, Not Otherwise Specified How To Differentiate and What To Do.ts
Hodgkin Lymphoma Updates Relapse After Auto-HCT, Brentuximab Vedotin, and Checkpoint Inhibitors The Next Frontier.ts
How to Sequence Non-CAR T-Cell Therapy for Relapsed DLBCL.ts
Impact of the Immune Landscape on Hodgkin Lymphoma Prognosis and Treatment.ts
Mantle Cell Lymphoma Case-Based Approach to Management.ts
Post-Acute Outcomes After HL An Epidemiologic Perspective.ts
Prevention of CNS Progression in DLBCL.ts
Primary CNS Lymphoma Focus on Consolidation.ts
Prognostication and Treatment of Burkitt Lymphoma in the Modern Era.ts
Recent Advances in the Frontline Treatment of DLBCL Is There a New Standard of Care.ts
Sequencing of Therapies in R R MCL.ts
T-Cell Lymphomas Impact of Classification on Treatment.ts
Targeted Agents in Follicular Lymphoma Small Molecules.ts
Toxicities Associated With Chronic Therapies for Lymphoma Case Studies.ts
Treatment of 1st Relapsed Classical Hodgkin Lymphoma.ts
Treatment of Relapsed CNS Lymphomas.ts
Venous Thromboembolism in Lymphoma Risk Stratification, Prophylaxis, and Treatment.ts
Reviews
There are no reviews yet.